HK1098700A1 - Use of drug combinations for treating insulin resistance - Google Patents
Use of drug combinations for treating insulin resistanceInfo
- Publication number
- HK1098700A1 HK1098700A1 HK07106252.3A HK07106252A HK1098700A1 HK 1098700 A1 HK1098700 A1 HK 1098700A1 HK 07106252 A HK07106252 A HK 07106252A HK 1098700 A1 HK1098700 A1 HK 1098700A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- insulin resistance
- drug combinations
- treating insulin
- treating
- drug
- Prior art date
Links
- 206010022489 Insulin Resistance Diseases 0.000 title 1
- 239000000890 drug combination Substances 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57248604P | 2004-05-20 | 2004-05-20 | |
PCT/CA2005/000775 WO2005112949A1 (fr) | 2004-05-20 | 2005-05-20 | Utilisation de combinaisons medicamenteuses pour traiter la resistance a l'insuline |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1098700A1 true HK1098700A1 (en) | 2007-07-27 |
Family
ID=35428249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07106252.3A HK1098700A1 (en) | 2004-05-20 | 2007-06-12 | Use of drug combinations for treating insulin resistance |
Country Status (9)
Country | Link |
---|---|
US (1) | US8673964B2 (fr) |
EP (1) | EP1758597B1 (fr) |
JP (1) | JP5000493B2 (fr) |
CN (1) | CN1960735B (fr) |
AU (1) | AU2005245240B2 (fr) |
CA (1) | CA2566873C (fr) |
HK (1) | HK1098700A1 (fr) |
NZ (1) | NZ551128A (fr) |
WO (1) | WO2005112949A1 (fr) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8236759B2 (en) * | 2005-06-30 | 2012-08-07 | Ipsen Pharma Sas | GLP-1 pharmaceutical compositions |
WO2007082381A1 (fr) * | 2006-01-20 | 2007-07-26 | Diamedica Inc. | Compositions contenant (s)-béthanéchol et leur utilisation pour traiter la résistance à l'insuline, le diabète de type 2, l'intolérance au glucose et des troubles associés |
AU2007299920A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | PPAR Mediated Modulation of Neurogenesis |
US10004703B2 (en) | 2006-10-12 | 2018-06-26 | Biogen Chesapeake Llc | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels |
WO2008046014A1 (fr) | 2006-10-12 | 2008-04-17 | Remedy Pharmaceuticals, Inc. | Traitement de la maladie d'alzheimer utilisant des composés réduisant l'activité de canaux cationiques non sélectifs, activés par ca++, sensibles à l'atp et régulés par des récepteurs sur1 |
JP2010533657A (ja) * | 2007-07-20 | 2010-10-28 | ジェネシス ベンチャー インコーポレーテッド | アミロイドタンパク質に関係する疾患を治療するための組織カリクレイン |
WO2009039313A1 (fr) * | 2007-09-18 | 2009-03-26 | Stephen Wills | Contrôle de la glycémie, traitement du diabète et autres traitements avec des inhibiteurs de l'acétylcholinestérase |
PT2868315T (pt) | 2007-12-04 | 2017-09-04 | Remedy Pharmaceuticals Inc | Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos |
WO2009097443A2 (fr) | 2008-01-29 | 2009-08-06 | Remedy Pharmaceuticals, Inc. | Formulations liquides de composés actifs au niveau des récepteurs des sulfonylurées |
CA2716780A1 (fr) * | 2008-02-25 | 2009-09-03 | National University Corporation Hokkaido University | Agent prophylactique ou therapeutique pour le diabete ou l'obesite |
DK2349324T3 (en) | 2008-10-17 | 2017-12-11 | Sanofi Aventis Deutschland | COMBINATION OF AN INSULIN AND A GLP-1 AGONIST |
US8114445B2 (en) * | 2008-11-07 | 2012-02-14 | Reliv International Inc. | Dietary supplement for promoting wellness and weight loss and methods of administering the same |
JP5973918B2 (ja) | 2009-11-13 | 2016-08-23 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Glp−1アゴニスト及びメチオニンを含む薬学的組成物 |
KR101836070B1 (ko) | 2009-11-13 | 2018-03-09 | 사노피-아벤티스 도이칠란트 게엠베하 | Glp-1 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물 |
CA3225438A1 (fr) | 2010-07-19 | 2012-01-26 | Remedy Pharmaceuticals, Inc. | Procedes d'administration par voie intraveineuse de glyburide et autres medicaments |
PT2611458T (pt) | 2010-08-30 | 2016-12-16 | Sanofi Aventis Deutschland | Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2 |
WO2012139227A1 (fr) * | 2011-04-15 | 2012-10-18 | Scimar Ltd. | Utilisation de s-adénosylméthionine, de vitamine e et de vitamine c dans la prévention et le traitement d'un dysfonctionnement cardiovasculaire |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
CN108079281A (zh) | 2011-08-29 | 2018-05-29 | 赛诺菲-安万特德国有限公司 | 用于2型糖尿病患者中的血糖控制的药物组合 |
AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
WO2013173923A1 (fr) | 2012-05-25 | 2013-11-28 | Diamedica, Inc. | Formulations de kallikréine 1 de tissu humain pour l'administration parentérale et procédés associés |
ES2625548T3 (es) | 2012-06-04 | 2017-07-19 | DiaMedica Therapeutics Inc. | Isoformas de glicosilación de la calicreína-1 tisular humana |
TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
SG10201707324WA (en) * | 2013-03-12 | 2017-10-30 | Hmi Inc | Plant extracts with anti-diabetic and other useful activities |
CN103399112B (zh) * | 2013-07-24 | 2015-07-15 | 上海交通大学 | 一种盐酸二甲双胍含量的测定方法 |
WO2015017549A1 (fr) | 2013-07-30 | 2015-02-05 | University Of South Florida (A Florida Non-Profit Corporation) | Traitement d'une anomalie de l'enzyme protéine kinase c atypique |
SG11201604710XA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
CN114939156A (zh) | 2014-01-09 | 2022-08-26 | 赛诺菲 | 门冬胰岛素的稳定化药物制剂 |
CN105899191B (zh) | 2014-01-09 | 2020-06-16 | 赛诺菲 | 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂 |
CN104383523A (zh) * | 2014-10-22 | 2015-03-04 | 山西医科大学 | Cjc-1131降糖药物在治疗阿尔茨海默病的用途 |
CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
WO2016120380A1 (fr) * | 2015-01-29 | 2016-08-04 | Novo Nordisk A/S | Composition pharmaceutique pour l'administration de glp-1 par voie orale, comprenant un noyau de comprimé et un revêtement à libération conventionnelle |
JP6983070B2 (ja) | 2015-02-03 | 2021-12-17 | ユニヴァーシティー コート オブ ザ ユニヴァーシティー オブ セント アンドリューズ | No含有組成物 |
CN104623671B (zh) * | 2015-02-09 | 2017-11-17 | 徐云根 | 含有乙酰胆碱酯酶抑制剂和二甲双胍的复方药用组合物 |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
EP3307741B1 (fr) * | 2015-06-09 | 2020-10-28 | Bayer Pharma Aktiengesellschaft | Modulateurs allosteriques positifs du récepteur muscarinique m2 |
KR20190122706A (ko) | 2017-03-09 | 2019-10-30 | 다이어메디카 인코포레이티드 | 조직 칼리크레인 1의 투약 형태 |
SG11202006492SA (en) * | 2018-02-05 | 2020-08-28 | Cellix Bio Private Ltd | Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof |
EP3616714A1 (fr) * | 2018-08-28 | 2020-03-04 | LaCa Medical BV | Hypoglycémie protégée au lactate afin de traiter des conditions pathologiques dépendantes de la glycolyse, en particulier le cancer |
CA3126328A1 (fr) * | 2019-01-12 | 2020-07-16 | Cellix Bio Private Limited | Association d'un agoniste selectif du recepteur alpha-adrenergique ou d'un agent anticholinergique et d'acide lipoique et ses utilisations |
CA3237005A1 (fr) * | 2021-11-04 | 2023-05-11 | Wayne W. Lautt | Procedes et kits pour determiner un traitement de resistance a l'insuline |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9302462D0 (en) * | 1993-12-01 | 1993-12-01 | Semple Keith | Motor cycle centre-stand lock |
US5762922A (en) * | 1994-01-31 | 1998-06-09 | Ludwig Institute For Cancer Research | Antioxidants and intracellular gluthathione raising agents for therapeutic treatments |
WO2000019992A1 (fr) | 1998-10-06 | 2000-04-13 | The University Of Manitoba | Procede pour traiter la resistance insulinique par le monoxyde d'azote hepatique |
HUP0002628A2 (en) * | 2000-07-14 | 2002-06-29 | Keri Pharma Kft | Pharmaceutical combinations for treating diabetes |
KR20040053210A (ko) * | 2001-11-02 | 2004-06-23 | 화이자 프로덕츠 인크. | Pde9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료 |
US20030235609A1 (en) * | 2002-01-25 | 2003-12-25 | Lautt Wilfred Wayne | Use of cholinesterase antagonists to treat insulin resistance |
US20030181461A1 (en) * | 2002-01-25 | 2003-09-25 | Lautt Wilfred Wayne | Use of phosphodiesterase antagonists to treat insulin resistance |
US7622447B2 (en) * | 2002-01-25 | 2009-11-24 | Diamedica Inc. | Use of glutathione synthesis stimulating compounds in reducing insulin resistance |
-
2005
- 2005-05-20 CA CA2566873A patent/CA2566873C/fr active Active
- 2005-05-20 CN CN200580016223.6A patent/CN1960735B/zh active Active
- 2005-05-20 JP JP2007516916A patent/JP5000493B2/ja active Active
- 2005-05-20 US US11/597,032 patent/US8673964B2/en active Active
- 2005-05-20 WO PCT/CA2005/000775 patent/WO2005112949A1/fr active Application Filing
- 2005-05-20 EP EP05748807A patent/EP1758597B1/fr active Active
- 2005-05-20 AU AU2005245240A patent/AU2005245240B2/en active Active
- 2005-05-20 NZ NZ551128A patent/NZ551128A/en unknown
-
2007
- 2007-06-12 HK HK07106252.3A patent/HK1098700A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CA2566873C (fr) | 2013-02-12 |
WO2005112949A1 (fr) | 2005-12-01 |
EP1758597B1 (fr) | 2012-09-12 |
NZ551128A (en) | 2010-03-26 |
CA2566873A1 (fr) | 2005-12-01 |
CN1960735B (zh) | 2015-07-29 |
US8673964B2 (en) | 2014-03-18 |
JP2007538015A (ja) | 2007-12-27 |
AU2005245240A1 (en) | 2005-12-01 |
CN1960735A (zh) | 2007-05-09 |
EP1758597A4 (fr) | 2008-02-27 |
US20090233995A1 (en) | 2009-09-17 |
AU2005245240B2 (en) | 2010-04-29 |
JP5000493B2 (ja) | 2012-08-15 |
EP1758597A1 (fr) | 2007-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1098700A1 (en) | Use of drug combinations for treating insulin resistance | |
EP1728528A4 (fr) | Seringue pre-remplie | |
ZA200900707B (en) | Substituted spiroketal derivatives and use thereof as therapeutic drug for diabetes | |
ZA200805716B (en) | Use of nitrooxyderivative of drug for the treatment of muscular dystrophies | |
EP1802258A4 (fr) | Administration de medicament transdermique biosynchrone | |
GB0619860D0 (en) | Treatment of insulin resistance and disorders associated therewith | |
GB0625659D0 (en) | Therapeutic compounds and their use | |
EP1824388A4 (fr) | Canule hypodermique guide | |
EP2048152A4 (fr) | Dérivé spirocétal à cycles accolés et utilisation de celui-ci comme médicament dans le traitement du diabète | |
HK1086771A1 (en) | Disposable syringe | |
EP1889618A4 (fr) | Médicament combiné pour le traitement du diabète | |
EP1778261A4 (fr) | Compositions et procedes de traitement et de prevention de la resistance a l'insuline | |
EP1733732A4 (fr) | Agent ameliorant la resistance a l insuline | |
GB0511892D0 (en) | Syringe | |
EP1719514A4 (fr) | Medicament contre la douleur | |
GB2420713B (en) | Safe syringe | |
GB0425854D0 (en) | Therapeutic treatment | |
EP1886692A4 (fr) | Agent d amelioration de la resistance a l insuline | |
EP1894589A4 (fr) | Seringue jetable non reutilisable | |
GB0423173D0 (en) | Treatment of diabetes | |
SG126063A1 (en) | Methods for the treatment of insulin resistance and disease states characterized by insulin resistance | |
GB2445733B (en) | Medical syringe | |
GB0417339D0 (en) | Syringe | |
GB0614538D0 (en) | Therapeutic Compounds And Their Use | |
GB0413020D0 (en) | Hypodermic syringe |